Skip to main content
SpringerLink
Log in

Targeted therapy underused in HER2-positive breast cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by GlaxoSmithKline.

Reference

  • DaCosta Byfield S, et al. Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study. Journal of Oncology Practice : 22 Sep 2015. Available from: URL: http://doi.org/10.1200/JOP.2015.004747

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Targeted therapy underused in HER2-positive breast cancer. PharmacoEcon Outcomes News 738, 25 (2015). https://doi.org/10.1007/s40274-015-2507-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2507-x

Search

Navigation